Autoinjectors are devices designed to deliver a dose of medication to patients with ease, accuracy, and precision. These devices are commonly used for self-administration of medication and have become increasingly popular in recent years due to the growing prevalence of chronic diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis.
According to the latest market research report, the global autoinjectors market is expected to reach a value of USD 15709.6 million by 2025, growing at a CAGR of 16.6% during the forecast period of 2020-2025. This growth is driven by several factors, including the increasing prevalence of chronic diseases, the rising demand for self-administration of medication, and the development of new biologics and biosimilars.
One of the key drivers of the autoinjectors market is the increasing prevalence of chronic diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis. According to the World Health Organization, the number of people living with diabetes has risen from 108 million in 1980 to 422 million in 2014, and it is estimated to rise to 552 million by 2030. This rising prevalence of chronic diseases is driving the demand for self-administration of medication, which in turn is driving the growth of the autoinjectors market.
Another factor driving the growth of the autoinjectors market is the development of new biologics and biosimilars. Biologics are complex molecules that are used to treat a variety of chronic diseases such as cancer, rheumatoid arthritis, and multiple sclerosis. These molecules are often administered via injection and require high levels of accuracy and precision. The development of new biologics and biosimilars is driving the demand for autoinjectors, which can deliver these medications with ease and accuracy.
In terms of product type, prefilled autoinjectors are expected to hold the largest market share during the forecast period. This is due to the increasing demand for self-administration of medication and the ease of use of prefilled autoinjectors. Prefilled autoinjectors are also preferred by patients as they eliminate the need for separate syringes and needles, reducing the risk of needle-stick injuries.
Geographically, North America is expected to hold the largest share of the autoinjectors market during the forecast period. This is due to the presence of a large number of pharmaceutical companies in the region and the high prevalence of chronic diseases. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the increasing healthcare expenditure, rising awareness about the benefits of self-administration of medication, and the growing prevalence of chronic diseases in the region.
Some of the key players operating in the autoinjectors market include AbbVie Inc., Becton, Dickinson and Company, Eli Lilly and Company, Mylan N.V., Pfizer Inc., Ypsomed Holding AG, Amgen Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.
In conclusion, the global autoinjectors market is expected to witness significant growth during the forecast period, driven by the increasing prevalence of chronic diseases, the rising demand for self-administration of medication, and the development of new biologics and biosimilars. The prefilled autoinjectors segment is expected to hold the largest market share, while North America is expected to hold the largest regional share. The key players operating in the market are focused on developing innovative products and expanding their presence in emerging markets to tap into the growing demand for autoinjectors.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Knox Market Research journalist was involved in the writing and production of this article.
